EPI-589

DB16041InvestigationalSmall molecule

EPI-589 is under investigation in clinical trial NCT02460679 (Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)).

Formula / weight: C₁₄H₁₉NO₄ · 265.309 g/mol (avg)
Code names: EPI-589

Resolves to

Compound

UNIII4ZSB1Q2DUCAS1147883-03-1

Structure

InChIKeyBAANPNDZFYBQIB-CQSZACIVSA-NSMILESCC1=C(C)C(=O)C(CC[C@@](C)(O)C(N)=O)=C(C)C1=O

What you can answer from here — as of April 23, 2025

1Clinical trialPhase, status and sponsor resolved per trial

Which companies are running trials of EPI-589, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account